The pharma company has wowed investors with solid clinical data multiple times this year.
News & Analysis: ArQule
ARQL earnings call for the period ending June 30, 2019.
These biotech stocks have at least quadrupled in just over six months this year.
The pharmaceutical pipeline shined, and the business doubled its cash position.
Investors are increasingly optimistic about the company.
A new day, a new batch of promising interim data from an early-stage clinical study.
The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.
Stocks were poised to ease lower on Friday morning.
ARQL earnings call for the period ending March 31, 2019.
The oncology-focused pharma announced first-quarter 2019 operating results.